Redirecting to https://www.kitepharma.com/news/press-releases/2021/10/us-fda-approves-kites-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-bcell-acute-lymphoblastic-leukemia...

Click here if your browser doesn't automatically take you to this page.